Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
Phase 1
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: MEDI5117 PlaceboBiological: MEDI5117
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 39
- Registration Number
- NCT01559103
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Belfast, United Kingdom
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Phase 3
Completed
- Conditions
- ObesityObstructive Sleep ApnoeaMetabolism and Nutrition Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 359
- Registration Number
- NCT01557166
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Toronto, Ontario, Canada
Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia BHaemophilia AHealthy
- Interventions
- Drug: NNC172-2021Drug: placebo
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8
- Registration Number
- NCT01555749
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom
Efficacy and Safety of Levemir® Used as Basal Insulin
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 631
- Registration Number
- NCT01548248
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 423
- Registration Number
- NCT01548235
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Copenhagen S, Denmark
Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1037
- Registration Number
- NCT01545791
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Safety and Efficacy of Long-term Somatropin Treatment in Adults
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 752
- Registration Number
- NCT01543880
Safety and Efficacy of Long-term Somatropin Treatment in Children
Completed
- Conditions
- Growth Hormone Deficiency in ChildrenSmall for Gestational AgeTurner SyndromeGrowth Hormone DisorderFoetal Growth ProblemGenetic DisorderGrowth DisorderIdiopathic Short Stature
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5442
- Registration Number
- NCT01543867
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1889
- Registration Number
- NCT01542424
- Locations
- 🇲🇰
Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of
Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT01542450
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath